Aurora Cannabis Delivers Record Medical Cannabis Revenue and Robust Profit Growth in Fiscal Q2 2026
Medical Cannabis Outpaces, Accounting for 78% of Total Net Revenue
In its fiscal Q2 2026 results, Aurora Cannabis Inc. showcased a strong quarter led by its global medical cannabis segment, which achieved net revenue of $70.53 million—a 15% increase from the same period last year. Medical cannabis contributed a striking 78% of the company's consolidated net revenue, further underlining Aurora’s dominance in high-growth, high-margin markets like Australia, Germany, Poland, the UK, and Canada.
International medical cannabis sales alone rose by 22% year over year, reaching $42.65 million, reflecting Aurora’s deepening foothold across key global markets. The Canadian medical cannabis segment also performed robustly, delivering $27.88 million in revenue.
| Segment | Q2 2026 Revenue (C$M) | Year-Over-Year % Change | % of Total Net Revenue |
|---|---|---|---|
| Global Medical Cannabis | 70.53 | +15% | 78% |
| Consumer Cannabis | 6.87 | -34% | 8% |
| Plant Propagation (Bevo) | 11.56 | +34% | 13% |
| Total Net Revenue | 90.37 | +11% | 100% |
Adjusted EBITDA Soars 52%, Backed by Margin Improvements
Aurora's adjusted EBITDA jumped to $15.37 million, representing a 52% increase over the prior year period. Adjusted gross profit before fair value adjustments reached $51.8 million (up 22%), and the overall adjusted gross margin rose to 61% (up from 54%). Notably, medical cannabis net revenue boasted a margin of 69%, the highest among the company’s business segments.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Adjusted EBITDA (C$M) | 15.37 | 10.14 | +52% |
| Adjusted Gross Margin (Total Net Revenue) | 61% | 54% | +7 pts |
| Adjusted Gross Margin (Medical Cannabis) | 69% | 68% | +1 pt |
Shift in Revenue Mix Reflects Focus on High-Margin Segments
Aurora continues to shift its business toward more profitable verticals. While global medical cannabis grew, consumer cannabis revenue dropped 34% year over year as Aurora prioritized high-margin, GMP-manufactured products. Adjusted gross margin for consumer cannabis still improved to 27%, reflecting cost-saving efforts. Plant propagation (via Bevo) delivered 34% growth in revenue, although its margin dipped to 10% due to one-off quality-related write-offs.
Balance Sheet Remains Strong with $141.9M Cash and Debt-Free Cannabis Business
The company reported $141.9 million in cash and a debt-free cannabis business, offering ample flexibility to pursue growth opportunities. Working capital stood at $299.73 million at the end of the quarter. Aurora’s only remaining debt relates to Bevo Farms and is non-recourse in nature.
Outlook: Further Medical Revenue Growth and Positive Free Cash Flow Expected in Q3
Looking to fiscal Q3 2026, Aurora expects consolidated net revenue to increase year over year, led by an anticipated 8%–12% gain in its Global Medical Cannabis segment. Margins are projected to stay robust, and management anticipates positive free cash flow next quarter—a notable milestone for the business. The strategy remains centered on scaling high-margin, high-growth medical markets while managing costs and preserving a healthy balance sheet.
| Q3 2026 Guidance | Management Outlook |
|---|---|
| Global Medical Cannabis Revenue | +8% to +12% YoY |
| Adjusted Gross Margin (Total) | Remain Strong (Near Current Levels) |
| Free Cash Flow | Positive |
Key Takeaway: High-Margin Medical Focus Paying Off
Aurora’s latest results demonstrate the benefits of its focus on the expanding and profitable global medical cannabis sector. Strong margins, significant cash reserves, and a clean balance sheet give Aurora flexibility and resilience. As the company looks ahead to Q3 and beyond, investors will be watching whether it can continue its streak of revenue growth and margin improvements while successfully managing costs and capital. Aurora’s leadership in medical markets appears to be translating into tangible financial momentum—and it’s a trend that may continue if sector demand stays robust.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI